Reduced mRNA and protein expression of BCL-2 versus decreased mRNA and increased protein expression of BAX in breast cancer brain metastases: A real-time PCR and immunohistochemical evaluation

Neurological Research

Volumn 28, Issue 8, 2006, Pages 787-793

  Stark, Andreas M ^a   Pfannenschmidt, Saskia ^a   Tscheslog, Hauke ^a   Maass, Nicolai ^a   Rösel, Frank ^a   Mehdorn, H Maximilian ^a   Held Feindt, Janka ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

BAX; BCL 2brain; Metastases

Indexed keywords

MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; BRAIN METASTASIS; BRAIN TUMOR; BREAST CANCER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BCL-2-ASSOCIATED X PROTEIN; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33845400136     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164106X110364     Document Type: Article

References (30)

1. Arbit E, Wronski M. Clinical decision making in brain metastases. Neurosurg Clin N Am 1996; 7: 447-457
2. Ewend MG, Carey LA, Morris DE, et al. Brain metastases. Curr Treat Options Oncol 2001; 2: 537-547
3. Hall WA, Djalilian HR, Nussbaum ES, et al. Long-term survival with metastatic cancer to the brain. Med Oncol 2000; 17: 279-286
4. Schouten LJ, Rutten J, Huveneers HA, et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung melanoma. Cancer 2002; 94: 2698-2705
5. Wronski M, Arbit E, McCormick B. Surgical treatment of 70 patients with brain metastases from breast carcinoma. Cancer 1997; 80: 1746-1754
6. Balint EE, Vousden KH. Activation and activities of the p53 tumour suppressor protein. Br J Cancer 2001; 85: 1813-1823
7. Michael D, Oren M. The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 2002; 12: 53-59
8. Ashcroft M, Vousden KH. Regulation of p53 stability. Oncogene 1999; 18: 7637-7643
9. Shen Y, White E. p53-dependent apoptosis pathways. Adv Cancer Res 2001; 82: 55-84
10. Brady HJ, Gil-Gomez G. Bax. The pro-apoptotic Bcl-2 family member, Bax. Int J Biochem Cell Biol 1998; 30: 647-650
11. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-776
12. Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001; 29: 684-688
13. Basu A, Haldar S. The relationship between Bcl-2, Bax and p53: Consequences for cell cycle progression and cell death. Mol Hum Reprod 1998; 4: 1099-1109
14. Arnold SM, Young AB, Munn RK, et al. Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1 in paired primary tumors and brain metastasis. Clin Cancer Res 1999; 5: 4028-4033
15. Sjostrom J, Blomqvist C, Heikkila P, et al. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 2000; 6: 3103-3110
16. Elkak AE, Kirkpatrick K, Mears L, et al. Telomerase activity and Bcl-2 expression in human breast cancer. Eur J Surg Oncol 2002; 28: 14-18
17. Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004; 1644: 229-249
18. Chang J, Clark GM, Allred DC, et al. Survival of patients with metastatic breast carcinoma: Importance of prognostic markers of the primary tumor. Cancer 2003; 97: 545-553
19. Coradini D, Daidone MG. Biomolecular prognostic factors in breast cancer. Curr Opin Obstet Gynecol 2004; 16: 49-55
20. Sirvent JJ, Aguilar MC, Olona M, et al. Prognostic value of apoptosis in breast cancer (pT1-pT2). A TUNEL, p53, Bcl-2, bag-1 and Bax immunohistochemical study. Histol Histopathol 2004; 19: 759-770
21. Yang Q, Sakurai T, Yoshimura G, et al. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Oncol Rep 2003; 10: 121-125
22. Cornfield DB, Palazzo JP, Schwartz GF, et al. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: A study of a large cohort of patients treated with surgery alone. Cancer 2004; 100: 2317-2327
23. Linjawi A, Kontogiannea M, Halwani F, et al. Prognostic significance of p53, Bcl-2, and Bax expression in early breast cancer. J Am Coll Surg 2004; 198: 83-90
24. Kayaselcuk F, Nursal TZ, Polat A, et al. Expression of surviving, Bcl-2, P53 and bax in breast carcinoma and ductal intraepithelial neoplasia (DIN 1a). J Exp Clin Cancer Res 2004; 23: 105-112
25. Dimitrakakis C, Konstadoulakis M, Messaris E, et al. Molecular markers in breast cancer: Can we use c-erbB-2, p53, bcl-2 and bax gene expression as prognostic factors? Breast 2002; 11: 279-285
26. Redondo M, Garcia J, Rodrigo I, et al. Expression of bax and p53 proteins in the tumorigenesis and progression of breast carcinomas. Tumour Biol 2003; 24: 23-31
27. Liu J, Yin S, Reddy N, et al. Bax mediates the apoptosis-sensitizing effect of maspin. Cancer Res 2004; 64: 1703-1011
28. Chen Y, Kayano T, Takagi M. Dysregulated expression of bcl-2 and bax in oral carcinomas: Evidence of post-transcriptional control. J Oral Pathol Med 2000; 29: 63-69
29. Mengubas K, Riordan FA, Hoffbrand AV, et al. Co-ordinated downregulation of bcl-2 and bax expression during granulocytic macrophage-like differentiation of the HL60 promyelocytic leukaemia cell line. FEBS Lett 1996; 394: 356-360
30. Pulliam L, Zhou M, Stubblebine M, et al. Differential modulation of cell death proteins in human brain cells by tumor necrosis factor alpha and platelet activating factor. J Neurosci Res 1998; 54: 530-538